CRIS Stock Summary and Trading Ideas (Curis | NASDAQ:CRIS)

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis trades on the NASDAQ stock market under the symbol CRIS.

As of January 26, 2026, CRIS stock price declined to $0.92 with 169,917 million shares trading.

CRIS has a beta of 3.70, meaning it tends to be more sensitive to market movements. CRIS has a correlation of 0.40 to the broad based SPY ETF.

CRIS has a market cap of $11.89 million. This is considered a Sub-Micro Cap stock.

Last quarter Curis reported $3 million in Revenue and -$.49 earnings per share. This beat revenue expectation by $288,000 and exceeded earnings estimates by $.12.

In the last 3 years, CRIS traded as high as $20.00 and as low as $.77.

The top ETF exchange traded funds that CRIS belongs to (by Net Assets): VTI, VXF.

CRIS has underperformed the market in the last year with a return of -73.2%, while the SPY ETF gained +14.8%. In the last 3 month period, CRIS fell short of the market, returning -43.6%, while SPY returned +3.4%. However, in the most recent 2 weeks CRIS has outperformed the stock market by returning +11.3%, while SPY returned -0.2%.

CRIS support price is $.88 and resistance is $1.00 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRIS shares will trade within this expected range on the day.